Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Operating Expenses (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Operating Expenses data on record, last reported at $361.6 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 67.18% year-over-year to $361.6 million; the TTM value through Dec 2025 reached $1.2 billion, up 71.48%, while the annual FY2025 figure was $1.2 billion, 71.48% up from the prior year.
  • Operating Expenses reached $361.6 million in Q4 2025 per RVMD's latest filing, up from $315.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $361.6 million in Q4 2025 and bottomed at $47.5 million in Q1 2021.
  • Average Operating Expenses over 5 years is $144.1 million, with a median of $117.9 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 134.6% in 2023, then rose 19.69% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $62.4 million in 2021, then increased by 23.51% to $77.0 million in 2022, then surged by 134.6% to $180.7 million in 2023, then increased by 19.69% to $216.3 million in 2024, then skyrocketed by 67.18% to $361.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $361.6 million in Q4 2025, $315.3 million in Q3 2025, and $264.7 million in Q2 2025.